KeyBank National Association
CLDX icon

KeyBank National Association’s Celldex Therapeutics CLDX Stock Holding History

KeyBank National Association’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,356
Closed -$216K – 1162
2024
Q3 		$216K Buy
+6,356
New +$242K ﹤0.01% 1071
2023
Q2 		– Sell
-5,810
Closed -$209K – 1063
2023
Q1 		$209K Hold
5,810
– – ﹤0.01% 1005
2022
Q4 		$259K Buy
+5,810
New +$207K ﹤0.01% 921

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

KeyBank National Association's CLDX Position: Q4 2024 in Review

KeyBank National Association sold out of Celldex Therapeutics (CLDX) in Q4 2024, closing a stake of 6,356 shares — an estimated $216K sold.

KeyBank National Association first reported a position in CLDX in Q4 2022 and held it in 3 quarters. The position peaked at $259K in Q4 2022. 174 funds tracked by Wall St. Rank hold CLDX as of Q4 2024.

  • KeyBank National Association reported no remaining Celldex Therapeutics position as of Q4 2024 after selling out during the quarter.
  • KeyBank National Association sold 6,356 Celldex Therapeutics shares in Q4 2024, an estimated $216K.
  • KeyBank National Association first reported a position in Celldex Therapeutics in Q4 2022 and held it in 3 quarters.
  • KeyBank National Association's Celldex Therapeutics position peaked at $259K in Q4 2022.
  • 174 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2024.

Based on KeyBank National Association's 13F filing for Q4 2024, filed 6 Feb 2025.